FDA approves drug for restless legs syndrome

Article

The United States Food and Drug Administration has approved gabapentin enacarbil (Horizant) extended-release tablets as a once-daily treatment for moderate to severe restless legs syndrome (RLS).

The United States Food and Drug Administration has approved gabapentin enacarbil (Horizant) extended-release tablets as a once-daily treatment for moderate to severe restless legs syndrome (RLS).

Two 12-week clinical trials in adults showed improvement in RLS symptoms in patients taking gabapentin enacarbil compared with placebo. The drug may cause drowsiness and dizziness and can impair the ability to drive or operate complex machinery. It will carry a warning about possible suicidal thoughts and actions similar to the warnings on epilepsy drugs because when gabapentin enacarbil is metabolized it becomes gabapentin, which is used to treat epileptic seizures.

Related Videos
Exploring the intersection of heart health and women's health | Image Credit: cedars-sinai.org
Unlocking the benefits of DHEA | Image Credit: drannacabeca.com
Unlocking the power of oxytocin | Image credit: drannacabeca.com
Revolutionizing menopause management: A deep dive into fezolinetant | Image Credit: uvahealth.com.
Deciding the best treatment for uterine fibroids | Image Credit: jeffersonhealth.org.
Clinical pearls of pediatric dermatology | Image Credit: profiles.ucsf.edu
Approaching inflammatory vulvovaginal diseases | Image Credit: profiles.ucsf.edu.
Related Content
© 2024 MJH Life Sciences

All rights reserved.